Top Companies in the Point of Care Molecular Diagnostics

The global market for point-of-care molecular diagnostics is expected to reach USD 7.09 billion by 2030, from USD 4.30 billion in 2025, with a CAGR of 10.5%. Growth is mainly driven by the increasing prevalence of infectious diseases and cancer, which boosts demand for rapid and accurate testing solutions. Additionally, there is a growing focus on decentralized diagnostics to facilitate quick decision-making closer to patients. Increased investments in research and development further boost innovation, resulting in faster, more efficient testing technologies. These factors, along with increased awareness of early disease detection and ongoing technological progress, are propelling the expansion of the point-of-care molecular diagnostics market.

The key players in this market are Danaher Corporation (US), bioMérieux (France), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), QuidelOrtho Corporation (US), Co-Diagnostics, Inc. (US), Biocartis Group NV (Belgium), SD Biosensor, INC. (South Korea), genedrive plc (UK), Binx Health, Inc. (US), Molbio Diagnostics Pvt. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuantuMDx Group Ltd. (UK), DetectaChem (US), Labsystems Diagnostics Oy (Finland), Akonni Biosystems, Inc. (US), Ubiquitome Limited (New Zealand), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), OpGen, Inc. (US), Nuclein, LLC (US), Genes2Me (India), Axxin (Australia), and Huwel Lifesciences (India).

To know about the assumptions considered for the study download the pdf brochure

Danaher Corporation maintains a strong position in the point-of-care molecular diagnostics market, supported by its broad diagnostics portfolio and global operational scale. Leveraging the capabilities of its subsidiary Cepheid, the company delivers rapid molecular testing solutions across diverse clinical areas, including respiratory conditions and women’s health, among others. Its extensive distribution network and service infrastructure ensure dependable product availability worldwide, even in dynamic healthcare environments. To reinforce its leadership in the point-of-care molecular diagnostics space, Danaher actively engages in strategic partnerships and collaborations to enhance its technology base and expand its presence in high-growth diagnostic segments. In June 2025, Cepheid, a subsidiary of Danaher, announced that Health Canada issued Cepheid a medical device license for Xpert HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to help assess HIV viral load levels, which are used to monitor the effectiveness of antiretroviral therapy treatment.

bioMérieux is a key player in the point-of-care molecular diagnostics market, supported by its expansive global operations and strong manufacturing and research infrastructure. The company operates in over 150 countries across the Americas, Europe, the Middle East & Africa, and the Asia Pacific, with 18 production facilities and 20 R&D centers worldwide. With 43 subsidiaries globally, it maintains a well-integrated international presence. bioMérieux offers a robust portfolio of molecular testing solutions, which enables syndromic testing for infections in near-patient settings. Its strategic focus on innovation, especially expanding its test menu and improving automation and user-friendliness, has reinforced its position in decentralized diagnostics.

F. Hoffmann-La Roche Ltd. holds a prominent position in the point-of-care molecular diagnostics market, driven by its extensive global reach and well-established distribution infrastructure. With a presence across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, the company effectively balances both direct and indirect distribution channels to ensure broad and consistent market coverage. This diversified approach enables Roche to navigate regional demand variability efficiently. The company continues to strengthen its position in the market through targeted acquisitions and strategic collaborations, aimed at enhancing its diagnostic capabilities and expanding access to its molecular testing solutions worldwide. In January 2025, F. Hoffmann-La Roche Ltd. announced that the US Food and Drug Administration (FDA) had granted 510(k) clearance and a Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels that diagnose sexually transmitted infections at the point-of-care.

Market Ranking:

The top five players in the point-of-care molecular diagnostics market are Danaher Corporation, bioMérieux, F. Hoffmann-La Roche Ltd., Abbott Laboratories, and QIAGEN N.V. Danaher Corporation has a strong presence through its subsidiary Cepheid, offering rapid molecular testing platforms widely used in decentralized settings. bioMérieux offers advanced molecular solutions primarily targeting respiratory diseases, with a strong emphasis on delivering results in near-patient settings. F. Hoffmann-La Roche Ltd. leverages its global diagnostics capabilities to deliver high-performance molecular testing solutions tailored for near-patient use. Abbott Laboratories contributes to the market through its ID NOW platform, which offers fast and reliable results for respiratory and infectious diseases. QIAGEN N.V. supports the market with portable molecular testing systems and a diverse assay menu, enabling broader access to point-of-care testing across clinical and field settings. Together, these companies shape the competitive landscape of the point-of-care molecular diagnostics market through continuous innovation, broad product offerings, and global accessibility.

Related Reports:

Point of Care Molecular Diagnostics Market by Product & Service (Assays, Instruments, Software), Technology (RT-PCR, INAAT), Sample Type (Blood, Urine), Application (STD, HAI, Hepatitis, Cancer), and End User (Hospitals, Clinics) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com